Replies to post #1774 on GTC Biotherapeutics (fka GTCB)

[dewophile]

Isn't Japan one of the courtries where ATIII already carries a DIC indication?
The implication of course is that Atryn approval woudl be met with large market uptake up front

[DewDiligence]

>Would a Japanese Atryn clinical study take around 2 to 3 years to enroll, complete, get acceptance, and gain marketing approval, with 2010 a likely target for revenue from Japan if GTCB partners within next half year? Maybe Japan can use data from the US and Europe trials.<

That’s a reasonable timeline, IMO. A Japanese MAA will use ATryn data from Europe and the U.S. but at least one Japanese study will be needed.